- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT06568939
부작용을 평가하고 이전에 치료받은 비편평 비소세포폐암(NSCLC) 성인 참가자의 단일 요법으로 정맥(IV) 주입된 Telisotuzumab Vedotin(ABBV-399)이 신체를 통해 이동하는 방법에 대한 연구
이전에 치료받은 c-Met 과발현, EGFR 야생형, 국소 진행성/전이성 비편평 비소세포폐암 환자를 대상으로 두 가지 Telisotuzumab Vedotin 요법에 대한 제2상 공개 무작위 글로벌 연구
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-small cell lung cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. The purpose of this study is to assess how safe telisotuzumab vedotin is in adult participants with NSCLC. Change in disease activity and adverse events will be assessed.
Telisotuzumab vedotin is an investigational drug being developed for the treatment of NSCLC. Participants will be randomly assigned a treatment of telisotuzumab vedotin in 1 of 3 arms at an 1:1:1 ratio. Each group receives intravenous (IV) infusion of telisotuzumab vedotin at different doses. Approximately 150 adult participants with c-Met overexpressing NSCLC will be enrolled in the study at approximately 80 to 90 sites worldwide.
Participants will receive IV telisotuzumab vedotin at 1 of 3 dose regimens as part of a 3 year study duration.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
연구 개요
연구 유형
등록 (추정된)
단계
- 2 단계
연락처 및 위치
연구 연락처
- 이름: ABBVIE CALL CENTER
- 전화번호: 844-663-3742
- 이메일: abbvieclinicaltrials@abbvie.com
연구 장소
-
-
Arizona
-
Chandler, Arizona, 미국, 85224
- 모병
- Ironwood Cancer and Research Center /ID# 276370
-
-
Arkansas
-
Little Rock, Arkansas, 미국, 72205
- 모병
- University of Arkansas for Medical Sciences /ID# 272923
-
-
California
-
Los Angeles, California, 미국, 90067
- 모병
- Valkyrie Clinical Trials /ID# 271322
-
Los Angeles, California, 미국, 90025
- 모병
- Start Los Angeles /ID# 284999
-
Oxnard, California, 미국, 93030
- 모병
- FOMAT Medical Research - Clinica mi Salud by Focil Med /ID# 284816
-
-
Connecticut
-
New Haven, Connecticut, 미국, 06510
- 완전한
- Yale New Haven Hospital /ID# 271584
-
-
Florida
-
Jacksonville, Florida, 미국, 32256
- 모병
- Cancer Specialists of North Florida - Jacksonville - AC Skinner Parkway /ID# 270899
-
Ocala, Florida, 미국, 34474
- 모병
- Ocala Oncology Center /ID# 273697
-
Pembroke Pines, Florida, 미국, 33028
- 모병
- Memorial Hospital West /ID# 270313
-
St. Petersburg, Florida, 미국, 33701-4732
- 모병
- Comprehensive Hematology Oncology /ID# 270422
-
St. Petersburg, Florida, 미국, 33705
- 모병
- Florida Cancer Specialists - North /ID# 271995
-
West Palm Beach, Florida, 미국, 33401
- 모병
- Florida Cancer Specialists - East /ID# 271993
-
-
Georgia
-
Athens, Georgia, 미국, 30607
- 모병
- University Cancer and Blood Center /ID# 270969
-
Marietta, Georgia, 미국, 30060
- 모병
- Northwest Georgia Oncology Centers /ID# 275374
-
Savannah, Georgia, 미국, 31404
- 완전한
- Memorial University Medical Center /ID# 272467
-
-
Hawaii
-
Honolulu, Hawaii, 미국, 96819
- 모병
- Kaiser Permanente Moanalua Medical Center /ID# 272916
-
-
Illinois
-
Chicago, Illinois, 미국, 60607
- 모병
- University of Illinois Hospital and Health Sciences System /ID# 275345
-
Niles, Illinois, 미국, 60714
- 모병
- Illinois Cancer Specialists /ID# 274678
-
Peoria, Illinois, 미국, 61637-0001
- 모병
- OSF St. Francis Medical Center /ID# 281591
-
Springfield, Illinois, 미국, 62702
- 모병
- Springfield Clinic - First /ID# 272576
-
-
Nebraska
-
Lincoln, Nebraska, 미국, 68506
- 모병
- Nebraska Hematology-Oncology /ID# 272970
-
Omaha, Nebraska, 미국, 68130
- 모병
- Nebraska Cancer Specialists - Omaha - Wright Street /ID# 271527
-
-
Nevada
-
Reno, Nevada, 미국, 89502
- 모병
- Renown Regional Medical Center /ID# 273535
-
-
New Jersey
-
East Brunswick, New Jersey, 미국, 08816-4096
- 모병
- Astera Cancer Care /ID# 272359
-
Teaneck, New Jersey, 미국, 07666
- 모병
- Regional Cancer Care Associates /ID# 270783
-
-
New York
-
The Bronx, New York, 미국, 10461
- 모병
- Montefiore Medical Center - Einstein Campus /ID# 277169
-
Westbury, New York, 미국, 11590
- 모병
- Clinical Research Alliance (SMO/Network/Consortium) /ID# 270455
-
-
North Carolina
-
Pinehurst, North Carolina, 미국, 28374
- 모병
- FirstHealth of the Carolinas- Speciality Center /ID# 272924
-
-
Ohio
-
Perrysburg, Ohio, 미국, 43551
- 모병
- Mercy Health - Perrysburg Cancer Center /ID# 270536
-
Zanesville, Ohio, 미국, 43701
- 모병
- Genesis Healthcare System /ID# 273361
-
-
Pennsylvania
-
Sayre, Pennsylvania, 미국, 18840
- 모병
- Guthrie Robert Packer Hospital /ID# 270316
-
York, Pennsylvania, 미국, 17403
- 모병
- Cancer Care Associates Of York /ID# 270971
-
-
South Carolina
-
Charleston, South Carolina, 미국, 29425
- 모병
- Medical University of South Carolina /ID# 273272
-
Greenville, South Carolina, 미국, 29607
- 모병
- Saint Francis Cancer Center - Greenville /ID# 276368
-
-
Tennessee
-
Nashville, Tennessee, 미국, 37203
- 모병
- SCRI Oncology Partners /ID# 270162
-
-
Texas
-
Dallas, Texas, 미국, 75246
- 모병
- Texas Oncology - Dallas - Worth Street /ID# 278947
-
Tyler, Texas, 미국, 75702
- 모병
- Texas Oncology - Northeast Texas /ID# 272000
-
-
Utah
-
Ogden, Utah, 미국, 84405
- 모병
- Community Cancer Trials Of Utah /ID# 276598
-
-
Virginia
-
Fairfax, Virginia, 미국, 22031
- 모병
- Virginia Cancer Specialists - Fairfax /ID# 272004
-
-
Washington
-
Spokane, Washington, 미국, 99208
- 모병
- Medical Oncology Associates - Spokane /ID# 277172
-
Tacoma, Washington, 미국, 98405
- 모병
- Northwest Medical Specialties Tacoma /ID# 270534
-
-
-
-
-
São Paulo, 브라질, 01323-020
- 모병
- Hospital Alemao Oswaldo Cruz - Sao Paulo /ID# 272512
-
-
Ceará
-
Fortaleza, Ceará, 브라질, 60810-180
- 모병
- Suporte Nutricional e Quimioterapia LTDA - PRONUTRIR /ID# 273203
-
-
Paraná
-
Curitiba, Paraná, 브라질, 80510-130
- 모병
- Ictrials Pesquisa E Desenvolvimento /ID# 276681
-
-
Pará
-
Belém, Pará, 브라질, 66063-495
- 모병
- Cto - Centro De Tratamento Oncologico /ID# 276699
-
-
Pernambuco
-
Recife, Pernambuco, 브라질, 50040-000
- 모병
- Hospital De Cancer De Pernambuco /ID# 276104
-
-
Rio Grande do Norte
-
Natal, Rio Grande do Norte, 브라질, 59075-740
- 모병
- Liga Norte Riograndense Contra O Cancer /ID# 273183
-
-
Rio Grande do Sul
-
Ijuí, Rio Grande do Sul, 브라질, 98700-000
- 모병
- Oncosite - Centro de Pesquisa Clinica em Oncologia /ID# 272513
-
-
Santa Catarina
-
Florianópolis, Santa Catarina, 브라질, 88020-210
- 모병
- Cepen - Centro De Pesquisa E Ensino Em Oncologia De Santa Catarina /ID# 273204
-
-
-
-
Beograd
-
Belgrade, Beograd, 세르비아, 11000
- 모병
- Institute for Oncology and Radiology of Serbia /ID# 270561
-
Belgrade, Beograd, 세르비아, 11080
- 모병
- Clinical Hospital Center - Bezanijska Kosa /ID# 270558
-
Belgrade, Beograd, 세르비아, 11000
- 모병
- University Clinical Center Serbia /ID# 270808
-
Belgrade, Beograd, 세르비아, 11000
- 모병
- Military Medical Academy /ID# 279873
-
-
Nisavski Okrug
-
Niš, Nisavski Okrug, 세르비아, 18300
- 모병
- University Clinical Center Nis /ID# 270557
-
-
Sremski Okrug
-
Kamenitz, Sremski Okrug, 세르비아, 21208
- 모병
- Institute For Pulmonary Diseases Of Vojvodina /ID# 270559
-
-
Sumadijski Okrug
-
Kragujevac, Sumadijski Okrug, 세르비아, 34000
- 모병
- University Clinical Center Kragujevac /ID# 275773
-
-
-
-
Central Singapore
-
Singapore, Central Singapore, 싱가포르, 169611
- 모병
- National Cancer Centre Singapore /ID# 271499
-
Singapore, Central Singapore, 싱가포르, 119074
- 모병
- National University Hospital /ID# 271700
-
-
-
-
-
Haifa, 이스라엘, 3109601
- 모병
- Rambam Health Care Campus- Haifa /ID# 270078
-
Jerusalem, 이스라엘, 9103102
- 완전한
- Shaare Zedek Medical Center /ID# 270095
-
-
Central District
-
Kefar Sava, Central District, 이스라엘, 4428164
- 모병
- Meir Medical Center /ID# 270071
-
Petah Tikva, Central District, 이스라엘, 4941492
- 모병
- Rabin Medical Center. /ID# 270087
-
-
Tel Aviv
-
Ramat Gan, Tel Aviv, 이스라엘, 5265601
- 모병
- The Chaim Sheba Medical Center /ID# 270068
-
-
-
-
Aichi-ken
-
Nagoya, Aichi-ken, 일본, 466-8560
- 모병
- Nagoya University Hospital /ID# 277010
-
-
Chiba
-
Kashiwa-shi, Chiba, 일본, 277-8577
- 모병
- National Cancer Center Hospital East /ID# 277056
-
-
Hokkaido
-
Sapporo, Hokkaido, 일본, 060-8648
- 모병
- Hokkaido University Hospital /ID# 277014
-
-
Hyōgo
-
Kobe, Hyōgo, 일본, 650-0046
- 모병
- Kobe Minimally Invasive Cancer Center /ID# 277469
-
-
Kanagawa
-
Sagamihara-shi, Kanagawa, 일본, 252-0375
- 모병
- Kitasato University Hospital /ID# 277012
-
-
Miyagi
-
Sendai, Miyagi, 일본, 981-0914
- 모병
- Sendai Kousei Hospital /ID# 277023
-
-
Miyazaki
-
Miyazaki, Miyazaki, 일본, 889-1692
- 모병
- University of Miyazaki Hospital /ID# 277020
-
-
Okayama-ken
-
Kurashiki-shi, Okayama-ken, 일본, 710-8602
- 모병
- Kurashiki Central Hospital /ID# 276995
-
-
Shizuoka
-
Fujieda, Shizuoka, 일본, 426-0077
- 모병
- Fujieda Municipal General Hospital /ID# 277025
-
-
Wakayama
-
Wakayama, Wakayama, 일본, 641-8510
- 모병
- Wakayama Medical University Hospital /ID# 276997
-
-
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, 중국, 101149
- 모병
- Beijing Chest Tumor Hospital /ID# 271935
-
-
Fujian
-
Fuzhou, Fujian, 중국, 350014
- 모병
- Fujian Province Cancer Hospital /ID# 276178
-
-
Guangxi
-
Nanning, Guangxi, 중국, 530021
- 모병
- Affiliated Cancer Hospital of Guangxi Medical University /ID# 271931
-
-
Heilongjiang
-
Harbin, Heilongjiang, 중국, 150081
- 모병
- Harbin Medical University Cancer Hospital /ID# 271665
-
-
Henan
-
Zhengzhou, Henan, 중국, 450008
- 모병
- Henan Cancer Hospital /ID# 271927
-
-
Hubei
-
Wuhan, Hubei, 중국, 430022
- 모병
- Union Hospital - Tongji Medical College /ID# 271668
-
-
Jiangxi
-
Nanchang, Jiangxi, 중국, 330006
- 모병
- The First Affiliated Hospital of Nanchang University /ID# 271666
-
-
Shaanxi
-
Xi'an, Shaanxi, 중국, 710061
- 모병
- The First Affiliated Hospital of Xi'an Jiaotong University /ID# 271928
-
-
Shandong
-
Linyi, Shandong, 중국, 276001
- 모병
- LinYi Cancer Hospital /ID# 272068
-
-
Xinjiang
-
Ürümqi, Xinjiang, 중국, 830011
- 모병
- Cancer Hospital Affliated to Xinjiang Medical University /ID# 271933
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Projected life expectancy of at least 12 weeks.
- Must have c-Met overexpressing non-small cell lung cancer (NSCLC) (defined as >= 25% tumor cells with 3+ staining (high [>= 50% 3+]; intermediate [>= 25% - < 50%]) as assessed by a Sponsor designated immunohistochemistry (IHC) laboratory
- Must have histologically or cytologically documented NSCLC that is locally advanced or metastatic.
- Must have a known epidermal growth factor receptor (EGFR) activating mutation status.
- Actionable alterations in genes other than EGFR are permitted.
- Must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
- Must have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1.
- Must have received no more than 1 line of prior systemic cytotoxic chemotherapy in the locally advanced or metastatic setting, as stated in the protocol.
- Must have progressed on at least 1 line of prior therapy for locally advanced/metastatic NSCLC, as stated in the protocol.
Exclusion Criteria:
- Adenosquamous or neuroendocrine histology, or sarcomatoid features.
- EGFR activating mutations (e.g., EGFR Exon 19 deletions, T790M, Exon 21 L858R, or Exon 20 insertion mutations).
- Received prior c-Met-targeted antibodies, prior telisotuzumab vedotin, or prior antibody-drug conjugates either targeting c-Met or consisting of monomethylauristatin E.
- Received prior docetaxel therapy.
- Metastases to the central nervous system (CNS). Participants with CNS metastases are eligible only after adequate treatment (such as surgery or, radiotherapy, or drug therapy) is provided, as stated on the protocol.
- History of other malignancies except those stated in the protocol.
- History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan, as noted in the protocol.
- Unresolved clinically significant adverse event (AE) >= Grade 2 from prior anticancer therapy, except for alopecia or anemia. Participants with hormone deficiencies caused by prior anticancer therapy who are asymptomatic and on a stable dose of replacement hormone are eligible for study.
- Major surgery within 21 days prior to randomization.
- Clinically significant condition(s) including but not limited to those listed in the protocol.
- Clinically significant liver disease, including hepatitis, current alcohol abuse, or cirrhosis.
- Grade >= 2 edema or lymphedema.
- Grade >= 2 ascites or pleural effusion.
- Grade >= 2 neuropathy.
- Active uncontrolled bacterial or viral infection.
- Active corneal disorder.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Telisotuzumab Vedotin Dose A
Participants will receive telisotuzumab vedotin dose A, as part of the 3 year study duration. |
Intravenous (IV) Infusion
다른 이름들:
|
|
실험적: Telisotuzumab Vedotin Dose B
Participants will receive telisotuzumab vedotin dose B, as part of the 3 year study duration. |
Intravenous (IV) Infusion
다른 이름들:
|
|
실험적: Telisotuzumab Vedotin Dose C
Participants will receive telisotuzumab vedotin dose C, as part of the 3 year study duration. |
Intravenous (IV) Infusion
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Percentage of Participants with Treatment-Emergent Adverse Events (AE)s (Any-grade and Grade >= 2)
기간: Up to Approximately 3 Years
|
An AE is defined as any untoward medical occurrence, inappropriate participant management decision, unintended disease or injury or any untoward clinical signs (including an abnormal laboratory finding) in participants, users or other persons whether or not related to the investigational medical device. |
Up to Approximately 3 Years
|
|
Percentage of Participants with Treatment-Emergent Interstitial Lung Disease (ILD)
기간: Up to Approximately 3 Years
|
ILD is defined by ILD standardized MedDRA query (SMQ) (broad) per investigator and determined per adjudication (any-grade and Grade >= 2). |
Up to Approximately 3 Years
|
|
Percentage of Participants with Treatment-Emergent Peripheral Neuropathy
기간: Up to Approximately 3 Years
|
Peripheral neuropathy is defined by peripheral neuropathy SMQ (narrow) (any-grade and Grade >= 2) |
Up to Approximately 3 Years
|
|
Percentage of Participants with Treatment-Emergent Ocular Surface Disorders
기간: Up to Approximately 3 Years
|
Treatment-emergent ocular surface disorders defined by corneal epitheliopathy company MedDRA query (CMQ) (any-grade and Grade >= 2). |
Up to Approximately 3 Years
|
|
Percentage of Participants with Treatment-Emergent AEs Leading to Study Drug Discontinuation
기간: Up to Approximately 3 Years
|
An AE is defined as any untoward medical occurrence, inappropriate participant management decision, unintended disease or injury or any untoward clinical signs (including an abnormal laboratory finding) in participants, users or other persons whether or not related to the investigational medical device. |
Up to Approximately 3 Years
|
|
Percentage of Participants with Grade 5 Treatment-Emergent AEs
기간: Up to Approximately 3 Years
|
An AE is defined as any untoward medical occurrence, inappropriate participant management decision, unintended disease or injury or any untoward clinical signs (including an abnormal laboratory finding) in participants, users or other persons whether or not related to the investigational medical device. |
Up to Approximately 3 Years
|
|
Objective Response (OR) by Blinded Independent Central Review (BICR)
기간: Up to Approximately 3 Years
|
OR will be defined as achieving confirmed complete response (CR) or confirmed partial response (PR) based on response evaluation criteria in solid tumors (RECIST), version 1.1. |
Up to Approximately 3 Years
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Concentrations of Telisotuzumab Vedotin Conjugate in Serum
기간: Up to 26 Weeks
|
Concentrations of telisotuzumab vedotin conjugate in serum. |
Up to 26 Weeks
|
|
Concentrations of Monomethylauristatin E (MMAE) Payload in Plasma
기간: Up to 26 Weeks
|
Concentrations of MMAE payload in plasma. |
Up to 26 Weeks
|
|
Percentage of Participants with Antidrug Antibodies (ADAs) of Telisotuzumab Vedotin
기간: Up to 26 Weeks
|
Percentage of participants with ADAs of telisotuzumab vedotin. |
Up to 26 Weeks
|
|
Percentage of Participants with Neutralizing Antidrug Antibodies (nADAs) of Telisotuzumab Vedotin
기간: Up to 26 Weeks
|
Percentage of participants with nADAs of telisotuzumab vedotin. |
Up to 26 Weeks
|
|
Change in Selected items of the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
기간: Cycle 1: Day 1, Day 8, Cycle 2 D1 and D1 of Every Even Cycle Thereafter, Through 3 Years
|
The PRO-CTCAE is a patient-reported outcome measurement system developed to assess symptomatic toxicity in patients participating in cancer clinical trials. PRO-CTCAE includes 124 items representing 78 symptomatic toxicities drawn from the Common Terminology Criteria for Adverse Events (CTCAE). PRO-CTCAE items evaluate the symptom attributes of frequency, severity, interference, amount, presence/absence. All questions employ a 7-day recall period and are scored from 0 to 4 (or 0/1 for absent/present). |
Cycle 1: Day 1, Day 8, Cycle 2 D1 and D1 of Every Even Cycle Thereafter, Through 3 Years
|
|
Change in GP5 item of the Functional Assessment of Cancer Therapy-General (FACT-G)
기간: Cycle 1: Day 1, Day 8, Cycle 2 D1 and D1 of Every Even Cycle Thereafter, Through 3 Years
|
The GP5 item ("I am bothered by side effects of treatment") of FACT-G is used to assess overall treatment tolerability in patients by assessing the overall side effect impact on participants. |
Cycle 1: Day 1, Day 8, Cycle 2 D1 and D1 of Every Even Cycle Thereafter, Through 3 Years
|
|
Duration of Response (DoR) by BICR
기간: Up to Approximately 3 Years
|
DoR is defined for confirmed responders as the time from the participants' initial response (CR or PR) to the first occurrence of radiographic progression per RECIST v1.1 or death from any cause. |
Up to Approximately 3 Years
|
|
Progression-Free Survival (PFS) by BICR
기간: Up to Approximately 3 Years
|
PFS will be defined as the time from randomization to the first occurrence of radiographic progression based on RECIST version 1.1 or death from any cause. |
Up to Approximately 3 Years
|
|
Overall Survival (OS)
기간: Up to Approximately 3 Years
|
OS will be defined as the time from randomization to death from any cause. |
Up to Approximately 3 Years
|
공동 작업자 및 조사자
스폰서
수사관
- 연구 책임자: ABBVIE INC., AbbVie
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- M25-274
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.
IPD 공유 기간
For details on when studies are available for sharing, visit https://vivli.org/ourmember/abbvie/
IPD 공유 액세스 기준
To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
IPD 공유 지원 정보 유형
- 연구_프로토콜
- 수액
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
미국에서 제조되어 미국에서 수출되는 제품
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .